Relevance of Poly (ADP-ribose) Polymerase Inhibitors in Prostate Cancer

Overview

Journal Curr Opin Support Palliat Care

Specialties Critical Care
Pharmacology

Date 2018 Jul 7

PMID 29979319

Citations 6

Authors

Pasquale Rescigno

Robert Chandler

Johann de Bono

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved drugs for the treatment of ovarian and breast cancer and currently under investigation for the treatment of prostate cancer and other malignancies with aberrations in homologous recombination DNA repair.This review summarizes literature published during 2017 concerning the relevance of PARPi in prostate cancer and presents new evidence on mechanisms of resistance and biomarkers of response.

Recent Findings: The approval of several PARPi (olaparib, rucaparib, and niraparib) has driven the focus of anticancer treatment on synthetic lethality in prostate cancer too. Despite anecdotal reports of long-term responders, most cancers become resistant to these therapies.Different mechanisms of primary and acquired resistance to PARPi have been recently investigated including loss of PARP1 expression, BRCA mutations with partial function, and acquisition of reversion restoration of function mutations.

Summary: Here, we discuss the importance of PARPi in metastatic castration-resistant prostate cancer and discuss the possible mechanisms of resistance.

Citing Articles

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.

Yehya A, Ghamlouche F, Zahwe A, Zeid Y, Wakimian K, Mukherji D Cancer Drug Resist. 2022; 5(3):667-690.

PMID: 36176747 PMC: 9511807. DOI: 10.20517/cdr.2022.15.

A Risk Model Developed Based on Homologous Recombination Deficiency Predicts Overall Survival in Patients With Lower Grade Glioma.

Peng H, Wang Y, Wang P, Huang C, Liu Z, Wu C Front Genet. 2022; 13:919391.

PMID: 35846118 PMC: 9283922. DOI: 10.3389/fgene.2022.919391.

Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer.

Li Y, Zhao Z, Ai L, Wang Y, Liu K, Chen B iScience. 2021; 24(10):103135.

PMID: 34622176 PMC: 8482486. DOI: 10.1016/j.isci.2021.103135.

Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.

He L, Fang H, Chen C, Wu Y, Wang Y, Ge H Medicine (Baltimore). 2020; 99(15):e19760.

PMID: 32282738 PMC: 7220391. DOI: 10.1097/MD.0000000000019760.

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.

Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A Int J Mol Sci. 2019; 20(12).

PMID: 31242618 PMC: 6627216. DOI: 10.3390/ijms20123100.